Patterns of pharmacological maintenance treatment in a community mental health services bipolar disorder cohort study (SIN-DEPRES)

International Journal of Neuropsychopharmacology

Volumn 16, Issue 3, 2013, Pages 513-523

  Grande, Iria ^a   De Arce, Rosario ^b   Jiménez Arriero, Miguel Ángel ^c   Lorenzo, Federico Guillermo Iglesias ^d   Valverde, Juan Ignacio Franch ^e   Balanzá Martínez, Vicent ^f   Zaragoza, Silvia ^g   Cobaleda, Silvia ^h   Vieta, Eduard ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d Universidad de La Coruña   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^f UNIVERSITY OF VALENCIA   (Spain)

^g Neuropsychological Research Organization   (Spain)

^h GLAXOSMITHKLINE   (Spain)

Author keywords

Bipolar disorder; community mental health services; cross sectional studies; drug therapy

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; LITHIUM; PSYCHOTROPIC AGENT;

ADULT; ARTICLE; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CLINICAL FEATURE; CLINICAL GLOBAL IMPRESSION SCALE; COHORT ANALYSIS; COMMUNITY MENTAL HEALTH; COMORBIDITY; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; HAMILTON SCALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; OUTPATIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RAPID CYCLING BIPOLAR DISORDER; RELAPSE; TREATMENT DURATION;

ADULT; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; COHORT STUDIES; COMMUNITY MENTAL HEALTH SERVICES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84874597564     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145712000405     Document Type: Article

References (50)

1. APA (2002). Practice guideline for the treatment of patients with bipolar disorder (revision). American Journal of Psychiatry 159(4 Suppl.), 1-50.
2. Baldessarini RJ, Leahy L, Arcona S, Gause D, et al. (2007). Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. Psychiatric Services (Washington, DC) 58, 85-91.
3. Bellantuono C, Barraco A, Rossi A, Goetz I (2007). The management of bipolar mania: A national survey of baseline data from the EMBLEM study in Italy. BMC Psychiatry 7, 33.
4. Bobes J, Bulbena A, Luque A, Dal-Re R, et al. (2003). A comparative psychometric study of the Spanish versions with 6, 17, and 21 items of the Hamilton Depression Rating Scale. Medicina Cĺnica 120, 693-700. (Pubitemid 36798871)
5. Bonnn CM, Sanchez-Moreno J, Martnez-Aran A, Sole B, et al. (2012). Subthreshold symptoms in bipolar disorder : impact on neurocognition, quality of life and disability. Journal of Affective Disorders 136, 650-659.
6. Colom F, Vieta E, Daban C, Pacchiarotti I, et al. (2006). Clinical and therapeutic implications of predominant polarity in bipolar disorder. Journal of Affective Disorders 93, 13-17. (Pubitemid 43816068)
7. Fountoulakis KN, Vieta E, Sanchez-Moreno J, Kaprinis SG, et al. (2005). Treatment guidelines for bipolar disorder : A critical review. Journal of Affective Disorders 86, 1-10. (Pubitemid 40487954)
8. Franchini L, Zanardi R, Smeraldi E, Gasperini M (1999). Early onset of lithium prophylaxis as a predictor of good long-term outcome. European Archives of Psychiatry and Clinical Neuroscience 249, 227-230. (Pubitemid 29537524)
9. Frye MA, Ha K, Kanba S, Kato T, et al. (2011). International consensus group on depression prevention in bipolar disorder. Journal of Clinical Psychiatry 72, 1295-1310.
10. Ghaemi SN, Hsu DJ, Thase ME, Wisniewski SR, et al. (2006). Pharmacological Treatment Patterns at Study Entry for the First 500 STEP-BD Participants. Psychiatric Services (Washington, DC) 57, 660-665.
11. Goodwin GM (2009). Evidence-based guidelines for treating bipolar disorder : revised second edition-recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology (Oxford, England) 23, 346-388.
12. Grof P, Duffy A, Cavazzoni P, Grof E, et al. (2002). Is response to prophylactic lithium a familial trait? Journal of Clinical Psychiatry 63, 942-947. (Pubitemid 35231736)
13. Grunze H, Vieta E, Goodwin GM, Bowden C, et al. (2010). The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders : Update 2010 on the treatment of acute bipolar depression. World Journal of Biological Psychiatry 11, 81-109.
14. Hirschfeld RMA, Vornik LA (2005). Bipolar disorder-costs and comorbidity. American Journal of Managed Care 11(3 Suppl.), S85-S90.
15. Hirschfeld RMA, Lewis L, Vornik LA (2003). Perceptions and impact of bipolar disorder : how far have we really come? Results of the national depressive and manicdepressive association 2000 survey of individuals with bipolar disorder. Journal of Clinical Psychiatry 64, 161-174. (Pubitemid 36268319)
16. Hosmer D, Lemeshow S (2000). Applied Logistic Regression, 2nd edn. New York: John Wiley.
17. Joffe RT, MacQueen GM, Marriott M, Trevor Young L (2004). A prospective, longitudinal study of percentage of time spent ill in patients with bipolar I or bipolar II disorders. Bipolar Disorders 6, 62-66. (Pubitemid 38256505)
18. Judd LL, Akiskal HS, Schettler PJ, Coryell W, et al. (2003). The comparative clinical phenotype and long term longitudinal episode course of bipolar I and II : A clinical spectrum or distinct disorders? Journal of Affective Disorders 73, 19-32. (Pubitemid 36044629)
19. Lobo A, Chamorro L, Luque A, Dal-Re R, et al. (2002). Validation of the Spanish versions of the Montgomery-Asberg depression and Hamilton anxiety rating scales [in Spanish]. Medicina Clinica (Barcelona) 118, 493-499. (Pubitemid 34814804)
20. MacQueen GM, Young LT, Robb JC, Marriott M, et al. (2000). Effect of number of episodes on wellbeing and functioning of patients with bipolar disorder. Acta Psychiatrica Scandinavica 101, 374-381. (Pubitemid 30233003)
21. Maier W, Philipp M, Heuser I, Schlegel S, et al. (1988). Improving depression severity assessment-I. Reliability, internal validity and sensitivity to change of three observer depression scales. Journal of Psychiatric Research 22, 3-12.
22. Mendlewicz J, Fieve RR, Stallone F (1973). Relationship between the effectiveness of lithium therapy and family history. American Journal of Psychiatry 130, 1011-1013.
23. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. British Journal of Psychiatry 34, 382-9. (Pubitemid 9136500)
24. Montoya A, Tohen M, Vieta E, Casillas M, et al. (2010). Functioning and symptomatic outcomes in patients with bipolar I disorder in syndromal remission: A 1-year, prospective, observational cohort study. Journal of Affective Disorders 127, 50-57.
25. Murru A, Colom F, Nivoli A, Pacchiarotti I, et al. (2011). When should mood stabilizers be withdrawn due to lack of efficacy? Some methodological considerations. European Psychiatry 26, 183-186.
26. National Collaborative Centre for Mental Health (2006). Bipolar Disorder : The Management of Bipolar Disorder in Adults, Children and Adolescents, in Primary and Secondary Care (Rep. No. NICE Clinical Guideline 38). London: National Collaborative Centre for Mental Health.
27. Nivoli AMA, Colom F, Murru A, Pacchiarotti I, et al. (2011a). New treatment guidelines for acute bipolar depression: A systematic review. Journal of Affective Disorders 129, 14-26.
28. Nivoli AMA, Murru A, Goikolea JM, Crespo JM, et al. (2011b). New treatment guidelines for acute bipolar mania: A critical review. Journal of Affective Disorders 129, 14-26.
29. Pacchiarotti I, Valent M, Bonnin CM, Rosa AR, et al. (2011). Factors associated with initial treatment response with antidepressants in bipolar disorder. European Neuropsychopharmacology 21, 362-369.
30. Perlis RH, Ostacher MJ, Patel JK, Marangell LB, et al. (2006). Predictors of recurrence in bipolar disorder : primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). American Journal of Psychiatry 163, 217-224. (Pubitemid 44480840)
31. Popovic D, Reinares M, Amann B, Salamero M, et al. (2011). Number needed to treat analyses of drugs used for maintenance treatment of bipolar disorder. Psychopharmacology 213, 657-667.
32. Popovic D, Reinares M, Goikolea JM, Bonnin CM, et al. (2012). Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder. European Neuropsychopharmacology 22, 339-346.
33. Rosa AR, Bonnin CM, Mazzarini L, Amann B, et al. (2009). Clinical predictors of interpersonal functioning in patients with bipolar disorder. Revista de Psiquiatria y Salud Mental 2, 83-88.
34. Rosa AR, Reinares M, Amann B, Popovic D, et al. (2011). Six-month functional outcome of a bipolar disorder cohort in the context of a specialized-care program. Bipolar Disorders 13, 679-686.
35. Sole B, Bonnin CM, Torrent C, Balanza-Martnez V, et al. (2012). Neurocognitive impairment and psychosocial functioning in bipolar II disorder. Acta Psychiatrica Scandinavica 125, 309-317.
36. Spearing MK, Post RM, Leverich GS, Brandt D, et al. (1997). Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP) : The CGI-BP. Psychiatry Research 73, 159-171. (Pubitemid 28088172)
37. Suppes T, Baldessarini RJ, Faedda GL, TohenM(1991). Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Archives of General Psychiatry 48, 1082-1088.
38. Suppes T, Dennehy EB, Hirschfeld RMA, Altshuler LL, et al. (2005). The Texas implementation of medication algorithms : update to the algorithms for treatment of bipolar I disorder. Journal of Clinical Psychiatry 66, 870-886. (Pubitemid 41032829)
39. Valent M, Pacchiarotti I, Rosa AR, BonnnCM, et al. (2011). Bipolar mixed episodes and antidepressants : A cohort study of bipolar I disorder patients. Bipolar Disorders 13, 145-154.
40. Vieta E, Rosa AR (2007). Evolving trends in the long-term treatment of bipolar disorder. World Journal of Biological Psychiatry 8, 4-11. (Pubitemid 46291196)
41. Vieta E, de Arce R, Jimenez-Arriero MA, Rodriguez A, et al. (2010a). Detection of subclinical depression in bipolar disorder : A cross-sectional, 4-month prospective follow-up study at community mental health services (SIN-DEPRES). Journal of Clinical Psychiatry 71, 1465-1474.
42. Vieta E, Gunther O, Locklear J, Ekman M, et al. (2011). Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder : A meta-analysis of randomized controlled trials. International Journal of Neuropsychopharmacology 14, 1029-1049.
43. Vieta E, Locklear J, Gunther O, Ekman M, et al. (2010b). Treatment options for bipolar depression: A systematic review of randomized, controlled trials. Journal of Clinical Psychopharmacology 30, 579-590.
44. Vieta E, Torrent Font C, Martnez-Aran A, Colom Victoriano F, et al. (2002). A user-friendly scale for the short and long term outcome of bipolar disorder : The CGI-BP-M. Actas Españ olas De Psiquiatŕa 30, 301-304. (Pubitemid 36302531)
45. Weiden PJ, Kozma C, Grogg A, Locklear J (2004). Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatric Services 55, 886-91. (Pubitemid 39025215)
46. WHO (2009). Anatomical Therapeutic Chemical (ATC)
47. WHO Experts Committee (1977). La selección de medicamentos esenciales Report No. 615. Geneva: World Health Organization.
48. Wolf T, Muller-Oerlinghausen B (2002). The influence of successful prophylactic drug treatment on cognitive dysfunction in bipolar disorders. Bipolar Disorders 4, 263-70. (Pubitemid 34846899)
49. Yatham LN, Kennedy SH, Schaffer A, Parikh SV, et al. (2009). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder : update 2009. Bipolar Disorders 11, 225-255.
50. Yildiz A, Vieta E, Leucht S, Baldessarini RJ (2011). Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology 36, 375-389.